IgE-Dependent and IgE-Independent Stimulation of Human Basophils Increases the Presence of Immature FcεRIα by Reversing Degradative PathwaysZaidi A.K. · MacGlashan, Jr. D.
Johns Hopkins Asthma and Allergy Center, Baltimore, Md., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Expression of the high-affinity IgE receptor, FcεRI, on mast cells and basophils has previously been shown to be sensitive to the presence of IgE or cytokines. The current study examined whether stimulation of human basophils resulted in a change in the expression of FcεRI. Methods: Changes in the well-expressed immature intracellular form of the receptor, FcεRIα (p46), were examined by quantitative PCR, Western blot and the pulse-chase method. Results: Both IgE-dependent (anti-IgE antibody) and IgE-independent stimulation [formyl-methionyl-leucyl-phenylalanine (FMLP) and C5a] led to increased accumulation of p46. The p46 form of FcεRIα increased 1.52 ± 0.09-, 2.58 ± 0.09- and 1.47 ± 0.07-fold following stimulation with anti-IgE, FMLP and C5a, respectively. There were no changes in the steady-state levels of mRNA for FcεRIα. The kinetics of the increase in p46 was slow following stimulation with anti-IgE antibody, with the earliest increases observed after 8 h. The p46 form was degraded in a bafilomycin A (lysosomal inhibitor)-sensitive process. There was no synergy between treatment with bafilomycin A and anti-IgE or FMLP stimulation, suggesting that the 2 methods of enhancement operate on the same pathway. Pulse-chase studies corroborated this conclusion. In contrast, IL-3 and bafilomycin A synergistically increased p46, suggesting that IL-3 increased synthesis of FcεRIα. Conclusions: Taken together, these results suggest that secretagogue stimulation results in an increase in p46 due to reversal of degradative pathways rather than increased synthesis of FcεRIα. Nevertheless, a decrease in the degradation of FcεRIα at an intermediate step in its processing by non-FcεRI-dependent stimulation may still influence expression of this important receptor.
© 2010 S. Karger AG, Basel
- MacGlashan DW Jr, Xia HZ, Schwartz LB, Gong JP: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol 2001;70:207–218.
- Borkowski TA, Jouvin MH, Lin SY, Kinet JP: Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 2001;167:1290–1296.
- Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, et al: IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999;162:5455–5465.
- Toru H, Ra C, Nonoyama S, Suzuki K, Yata J, Nakahata T: Induction of the high-affinity IgE receptor (FcεRI) on human mast cells by IL-4. Int Immunol 1996;8:1367–1373.
- Xia HZ, Du Z, Craig S, Klisch G, Noben-Trauth N, Kochan JP, et al: Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol 1997;159:2911–2921.
- Ryan JJ, DeSimone S, Klisch G, Shelburne C, McReynolds LJ, Han K, et al: IL-4 inhibits mouse mast cell Fc epsilonRI expression through a STAT6-dependent mechanism. J Immunol 1998;161:6915–6923.
- Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, et al: IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 2008;180:2848–2854.
- Youssef LA, Schuyler M, Gilmartin L, Pickett G, Bard JD, Tarleton CA, et al: Histamine release from the basophils of control and asthmatic subjects and a comparison of gene expression between ‘releaser’ and ‘nonreleaser’ basophils. J Immunol 2007;178:4584–4594.
- Isersky C, Rivera J, Segal DM, Triche T: The fate of IgE bound to rat basophilic leukemia cells. II. Endocytosis of IgE oligomers and effect on receptor turnover. J Immunol 1983;131:388–396.
- MacGlashan DW Jr: Endocytosis, recycling and degradation of unoccupied FcεRI in human basophils. J Leukoc Biol 2007;82:1003–1010.
- Saini S, Richardson JJ, Wofsy C, Lavens-Phillips, Bochner B, MacGlashan DW Jr: Expression and modulation of FcεRIα and FcεRIβ in human blood basophils. J Allergy Clin Immunol 2001;107:832–841.
- Albrecht B, Woisetschlager M, Robertson MW: Export of the high affinity IgE receptor from the endoplasmic reticulum depends on a glycosylation-mediated quality control mechanism. J Immunol 2000;165:5686–5694.
- Cauvi DM, Tian X, von Loehneysen K, Robertson MW: Transport of the IgE receptor alpha-chain is controlled by a multicomponent intracellular retention signal. J Biol Chem 2006;281:10448–10460.
- Fiebiger E, Tortorella D, Jouvin MH, Kinet JP, Ploegh HL: Cotranslational endoplasmic reticulum assembly of FcepsilonRI controls the formation of functional IgE-binding receptors. J Exp Med 2005;201:267–277.
- Letourneur O, Sechi S, Willette-Brown J, Robertson MW, Kinet JP: Glycosylation of human truncated Fc epsilon RI alpha chain is necessary for efficient folding in the endoplasmic reticulum. J Biol Chem 1995;270:8249–8256.
- Letourneur F, Hennecke S, Demolliere C, Cosson P: Steric masking of a dilysine endoplasmic reticulum retention motif during assembly of the human high affinity receptor for immunoglobulin E. J Cell Biol 1995;129:971–978.
- MacGlashan DW Jr, Schroeder JT: Functional consequences of FcεRIα up-regulation by IgE in human basophils. J Leukoc Biol 2000;68:479–486.
- Gilbert HS, Ornstein L: Basophil counting with a new staining method using alcian blue. Blood 1975;46:279–286.
- MacGlashan DW Jr: Relationship between spleen tyrosine kinase and phosphatidylinositol 5’ phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 2007;119:626–633.
- Hartman ML, Lin SY, Jouvin MH, Kinet JP: Role of the extracellular domain of Fc epsilon RI alpha in intracellular processing and surface expression of the high affinity receptor for IgE Fc epsilon RI. Mol Immunol 2008;45:2307–2311.
- Donnadieu E, Jouvin MH, Kinet JP: A second amplifier function for the allergy-associated Fc(epsilon)RI-beta subunit. Immunity 2000;12:515–523.
- Kraft S, Rana S, Jouvin MH, Kinet JP: The role of the FcepsilonRI beta-chain in allergic diseases. Int Arch Allergy Immunol 2004;135:62–72.
- Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP: Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989;337:187–189.
- Ravetch JV, Kinet JP: Fc receptors. Annu Rev Immunol 1991;9:457–492.
- MacGlashan D Jr: IgE receptor and signal transduction in mast cells and basophils. Curr Opin Immunol 2008;20:717–723.
- Matsuda A, Okayama Y, Ebihara N, Yokoi N, Gao P, Hamuro J, et al: High-affinity IgE receptor-beta chain expression in human mast cells. J Immunol Methods 2008;336:229–234.
- Schroeder JT, Chichester KL, Bieneman AP: Human basophils secrete IL-3: evidence of autocrine priming for phenotypic and functional responses in allergic disease. J Immunol 2009;182:2432–2438.
- Miura K, Saini SS, Gauvreau G, MacGlashan DW Jr: Differences in functional consequences and signal transduction induced by IL-3, IL-5 and nerve growth factor in human basophils. J Immunol 2001;167:2282–2291.
- Miura K, MacGlashan DW Jr: Dual phase priming by interleukin-3 for leukotriene C4 generation in human basophils. J Immunol 2000;164:3026–3034.
- Didichenko SA, Spiegl N, Brunner T, Dahinden CA: IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils. Blood 2008;112:3949–3958.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.